Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

This study is testing an alternative dosing schedule for a cancer drug called cabozantinib in people with kidney cancer (renal cell carcinoma) or a specific type of slow-growing tumor called a neuroendocrine tumor (NET). The goal is to see if a different schedule reduces side effects while keeping the drug effective. **You may be eligible if...** - You have been diagnosed with advanced kidney cancer (any type, including sarcomatoid) - Or you have been diagnosed with a well-differentiated neuroendocrine tumor (Grade 1–3, any primary site) - You may or may not have received prior treatment depending on which study group (cohort) you join - Your general health is adequate for cancer treatment **You may NOT be eligible if...** - You have previously received cabozantinib (for some cohorts) - You have uncontrolled high blood pressure or serious heart conditions - You are pregnant or breastfeeding - You have significant bleeding problems or recent blood clots Talk to your doctor to see if this trial is right for you.